Quantcast
Last updated on April 24, 2014 at 11:03 EDT

Latest Tumor M2-PK Stories

2014-01-07 12:27:48

LONDON, Jan. 7, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: MediPoint: In-Vitro Colorectal Cancer Screening Tests - South America Analysis and Market Forecasts MediPoint: In-Vitro Colorectal Cancer Screening Tests - South America Analysis and Market Forecasts Summary Colorectal cancer (CRC) is the third most commonly diagnosed cancer, and the second most common cause of mortality amongst cancer patients. Prognosis is directly related to early...

2013-10-28 23:04:58

Reportbuyer.com just published a new market research report: MediPoint: In-Vitro Colorectal Cancer Screening Tests - APAC Analysis and Market Forecasts. London (PRWEB) October 28, 2013 Summary Colorectal cancer (CRC) is the third most commonly diagnosed cancer, and the second most common cause of mortality amongst cancer patients. Prognosis is directly related to early diagnosis, with survival rates dramatically improved by early diagnosis and treatment. Thanks to the introduction of CRC...

2013-10-28 23:04:15

Reportbuyer.com just published a new market research report: MediPoint: In-Vitro Colorectal Cancer Screening Tests - US Analysis and Market Forecasts. London (PRWEB) October 28, 2013 Summary Colorectal cancer (CRC) is the third most commonly diagnosed cancer, and the second most common cause of mortality amongst cancer patients. Prognosis is directly related to early diagnosis, with survival rates dramatically improved by early diagnosis and treatment. Thanks to the introduction of CRC...

2013-10-28 23:03:59

Reportbuyer.com just published a new market research report: MediPoint: In-Vitro Colorectal Cancer Screening Tests - EU Analysis and Market Forecasts. London (PRWEB) October 28, 2013 Summary Colorectal cancer (CRC) is the third most commonly diagnosed cancer, and the second most common cause of mortality amongst cancer patients. Prognosis is directly related to early diagnosis, with survival rates dramatically improved by early diagnosis and treatment. Thanks to the introduction of CRC...

2012-11-27 13:06:13

PKM2 slips into nucleus to promote cancer; potential biomarker and drug approach discovered Researchers at The University of Texas MD Anderson Cancer Center have tracked down a cancer-promoting protein's pathway into the cell nucleus and discovered how, once there, it fires up a glucose metabolism pathway on which brain tumors thrive. They also found a vital spot along the protein's journey that can be attacked with a type of drug not yet deployed against glioblastoma multiforme, the...

2012-03-16 09:40:43

A powerful new strategy for personalized anti-cancer therapy Researchers at the Kimmel Cancer Center at Jefferson have demonstrated for the first time that the metabolic biomarker MCT4 directly links clinical outcomes with a new model of tumor metabolism that has patients "feeding" their cancer cells. Their findings were published online March 15 in Cell Cycle. To validate the prognostic value of the biomarker, a research team led by Agnieszka K. Witkiewicz, M.D., Associate Professor of...

2012-02-08 06:39:34

(Ivanhoe Newswire)-- When fighting tumors it is essential doctors target the metabolic reactions that fuel their growth. A new study shows that a one-size-fits-all metabolism-specific cancer therapy will not fight every type of cancer. Researchers say that metabolic profiling will be imperative for defining each type of cancer and choosing the best treatment option for a patient. Their evidence comes from observing mice that exhibit how tumors metabolic profiles vary. The variations...

2012-02-07 23:07:13

One way to tackle a tumor is to take aim at the metabolic reactions that fuel their growth. But a report in the February Cell Metabolism, a Cell Press Publication, shows that one metabolism-targeted cancer therapy will not fit all. That means that metabolic profiling will be essential for defining each cancer and choosing the best treatment accordingly, the researchers say. The evidence comes from studies in mice showing that tumors' metabolic profiles vary based on the genes underlying a...

2011-04-27 01:55:54

Among obese patients, activation of the protein biomarker CTNNB1 was associated with better colorectal cancer-specific survival and overall survival, whereas post-diagnosis physical activity was associated with better colorectal cancer-specific survival among patients negative for CTNNB1, according to a study in the April 27 issue of JAMA. Activation of the WNT signaling pathway (a network of proteins known for their roles in cancer) and cadherin-associated protein beta-1 (CTNNB1;...

2011-04-01 15:32:43

Researchers have found that it may not be necessary to look for tumors directly in patients with prostate cancer "” analyzing non-tumor tissue may be an effective option, according to study results published in Cancer Research, a journal of the American Association for Cancer Research. "A biopsy needle does not need to hit a tumor to detect the presence of tumor," said lead researcher Dan Mercola, M.D., Ph.D., professor of pathology and laboratory medicine at the University of...